ALKS Healthcare

Alkermes plc

$45.69+1.78%

Price as of close on Nov 3, 2026 · Financials updated Oct 31, 2026

Basics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Country: Ireland
Market cap: 7.7B USD
Enterprise value: 7.8B USD
Full-time employees: 2,050

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers
Drawback: more debt relative to equity (0.84× vs a peer median of 0.22×)more debt vs equity (0.84× vs peers 0.22×)
About average: profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk

Ranks #874 of 1,157 healthcare companies (bottom 25%)

See how it ranks against its peers

Worth knowing

Cash flow well above reported profit. Free cash flow is 3.4× reported profit.
Free cash flow is 3.4× reported profit. Large non-cash charges, such as depreciation, amortization or stock-based pay, reduce reported profit without using cash.

StockQuotient Score

37/ 100▲ 1 since Oct 27 close

Oct 5 37 → Nov 4 37

Valuation

Is the price right?

41/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield0.9%

SEC filings · 12 months to Jun 2026Reported value30% base weight · Z-score -0.42Sector median: 0.0148 · MAD: 0.0148

EBITDA yield2.1%

SEC filings · 12 months to Jun 2026Reported value50% base weight · Z-score -0.48Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield2.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingReported value20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield23.6%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

24/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 6.7%

Why

Weaker than most peers on:

▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growth-81.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score -2.79Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth4.5%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score -0.16Sector median: 0.0584 · MAD: 0.0840

Revenue growth10.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.48Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

47/100

Moderate▲ 1 since Oct 27 close

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Operating margin fell 5.3 points to 7.0%

Why it changed since the Oct 27, 2026 close: Score 46 → 47

Peer companies moved+1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Close to the peer norm on every measure.

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin7.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.00Sector median: 0.0706 · MAD: 0.1217

Return on assets1.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.03Sector median: 0.0166 · MAD: 0.0537

Return on invested capital3.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -0.14Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin84.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity3.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.27

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 1.04Sector median: 0.6250 · MAD: 0.3380

Current ratio2.30×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.21Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.84×

SEC filings · latest balance sheetReported value33% base weight · Z-score -3.05Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Alkermes

Is Alkermes getting weaker?: Its latest SEC filing (Jul 28, 2026) got weaker in some ways: operating margin fell 5.3 points to 7.0%. Its overall score is 37/100, up 1 since Oct 28, 2026.
How is Alkermes valued vs its peers?: Priced about in line with its peers. Valuation scores 41/100 against 1,393 healthcare peers.
Is Alkermes growing?: More slowly than most of its peers. Growth scores 24/100 against 1,393 healthcare peers. Revenue growth 10.8% vs a peer median of 6.1% (stronger than 63% of peers).Revenue growth 10.8% vs peers 6.1% (stronger than 63% of peers). Earnings per share growth -81.3% vs a peer median of 9.8% (weaker than 100% of peers).Earnings per share growth -81.3% vs peers 9.8% (weaker than 100% of peers).
How profitable is Alkermes?: About as profitable as its peers. Profitability scores 47/100 against 1,393 healthcare peers.
How risky is Alkermes?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.27 vs a peer median of 0.63 (stronger than 82% of peers).Beta 0.27 vs peers 0.63 (stronger than 82% of peers). Debt / equity 0.84× vs a peer median of 0.22× (weaker than 78% of peers).Debt / equity 0.84× vs peers 0.22× (weaker than 78% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Jul 28, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Operating margin fell 5.3 points to 7.0%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	1.6B USD	1.7B USD	+6.7%
Net income (12 months)	152.8M USD	66.2M USD	−56.7%
Operating margin	12.3%	7.0%	−5.3 pts
Free cash flow (12 months)	221.8M USD	221.7M USD	−0.1%
Debt	1.5B USD	1.5B USD	0.0%
Cash	351.6M USD	511.5M USD	+45.5%
Shares outstanding	166.7M	167.8M	+0.7%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	83.2%	80.4%	84.8%	84.2%	86.7%	▲ 2.4 pts
Operating margin	8.3%	-0.5%	24.9%	27.0%	17.2%	▼ 9.8 pts
Net margin	-4.1%	-14.2%	21.4%	23.6%	16.4%	▼ 7.2 pts
Return on assets (ROA)	-2.4%	-8.1%	16.7%	17.9%	9.7%	▼ 8.1 pts
Return on equity (ROE)	-4.3%	-15.2%	29.6%	25.1%	13.3%	▼ 12 pts
Free cash flow margin	6.3%	-1.5%	21.2%	26.0%	32.5%	▲ 6.5 pts
Current ratio	2.25×	2.27×	2.86×	3.04×	3.55×	▲ 17%
Quick ratio	1.93×	1.91×	2.50×	2.65×	3.19×	▲ 20%
Debt to equity	0.27×	0.28×	0.24×	—	—	—
Interest coverage	8.71×	-0.47×	17.98×	18.63×	20.69×	▲ 11%

ALKS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: growing more slowly than most peersgrowing more slowly than peers

Drawback: more debt relative to equity (0.84× vs a peer median of 0.22×)more debt vs equity (0.84× vs peers 0.22×)

About average: profitability, valuation and risk (debt, liquidity and share-price swings)profitability, valuation and risk

Ranks #874 of 1,157 healthcare companies (bottom 25%)

See how it ranks against its peers

Questions investors ask about Alkermes

Is Alkermes getting weaker?

Its latest SEC filing (Jul 28, 2026) got weaker in some ways: operating margin fell 5.3 points to 7.0%. Its overall score is 37/100, up 1 since Oct 28, 2026.

How is Alkermes valued vs its peers?

Priced about in line with its peers. Valuation scores 41/100 against 1,393 healthcare peers.

Is Alkermes growing?

More slowly than most of its peers. Growth scores 24/100 against 1,393 healthcare peers. Revenue growth 10.8% vs a peer median of 6.1% (stronger than 63% of peers).Revenue growth 10.8% vs peers 6.1% (stronger than 63% of peers). Earnings per share growth -81.3% vs a peer median of 9.8% (weaker than 100% of peers).Earnings per share growth -81.3% vs peers 9.8% (weaker than 100% of peers).

How profitable is Alkermes?

About as profitable as its peers. Profitability scores 47/100 against 1,393 healthcare peers.

How risky is Alkermes?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Beta 0.27 vs a peer median of 0.63 (stronger than 82% of peers).Beta 0.27 vs peers 0.63 (stronger than 82% of peers). Debt / equity 0.84× vs a peer median of 0.22× (weaker than 78% of peers).Debt / equity 0.84× vs peers 0.22× (weaker than 78% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

1.6B USD

1.7B USD

+6.7%

Net income (12 months)

152.8M USD

66.2M USD

−56.7%

Operating margin

12.3%

7.0%

−5.3 pts

Free cash flow (12 months)

221.8M USD

221.7M USD

−0.1%

Debt

1.5B USD

1.5B USD

0.0%

Cash

351.6M USD

511.5M USD

+45.5%

Shares outstanding

166.7M

167.8M

+0.7%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

83.2%

80.4%

84.8%

84.2%

86.7%

▲ 2.4 pts

Operating margin

8.3%

-0.5%

24.9%

27.0%

17.2%

▼ 9.8 pts

Net margin

-4.1%

-14.2%

21.4%

23.6%

16.4%

▼ 7.2 pts

Return on assets (ROA)

-2.4%

-8.1%

16.7%

17.9%

9.7%

▼ 8.1 pts

Return on equity (ROE)

-4.3%

-15.2%

29.6%

25.1%

13.3%

▼ 12 pts

Free cash flow margin

6.3%

-1.5%

21.2%

26.0%

32.5%

▲ 6.5 pts

Current ratio

2.25×

2.27×

2.86×

3.04×

3.55×

▲ 17%

Quick ratio

1.93×

1.91×

2.50×

2.65×

3.19×

▲ 20%

Debt to equity

0.27×

0.28×

0.24×

—

Interest coverage

8.71×

-0.47×

17.98×

18.63×

20.69×

▲ 11%